DA.ACI-(D10Rat2-D10Rat29)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
1 |
3.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68730 |
829 |
DA.ACI-(D10Rat2-D10Rat29)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
6 |
13.3 |
d |
2.6 |
6.37 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68731 |
829 |
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 7 |
22.4 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
40 |
days |
from 8 to 40 days |
|
69414 |
892 |
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 14 |
7.8 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
34 |
days |
from 8 to 34 days |
|
69434 |
892 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
male |
65 days-112 days |
21 |
11.7 |
d |
2.23 |
10.2 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69490 |
837 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
0 |
20.0 |
d |
|
8.5 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69501 |
837 |
LOU/M |
experimental autoimmune encephalomyelitis duration |
rat anti-Hu-MBP T cell line (9 x 10E6 cells) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
9 |
6.0 |
d |
1.0 |
3.0 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
110784 |
3186 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 16 |
6.8 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
40 |
days |
from 8 to 40 days |
days |
69386 |
892 |
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 14 |
18.4 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
40 |
days |
from 8 to 40 days |
|
69417 |
892 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
14 |
13.4 |
d |
2.2 |
8.23 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68209 |
829 |
DA.ACI-(D10Rat15-D10Rat29) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
5 |
13.4 |
d |
2.0 |
4.47 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68203 |
829 |
DA.ACI-(D10Rat219-D10Rat29) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
6 |
11.5 |
d |
2.6 |
6.37 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68215 |
829 |
DA.ACI-(D10Rat10-D10Rat142) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
6 |
13.5 |
d |
3.1 |
7.59 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68218 |
829 |
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 24 |
5.5 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
37 |
days |
from 8 to38 days |
days |
69383 |
892 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 10 |
23.8 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
40 |
days |
from 8 to 40 days |
|
69411 |
892 |
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 19 |
11.2 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
28 |
days |
from 8 to 28 days |
|
69421 |
892 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 17 |
9.0 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
34 |
days |
from 8 to 34 days |
|
69425 |
892 |
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 9 |
5.9 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
34 |
days |
from 8 to 34 days |
|
69432 |
892 |
DA.ACI-(D10Rat15-D10Rat29) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
10 |
8.6 |
d |
1.5 |
4.74 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68227 |
829 |
DA.ACI-(D10Rat219-D10Rat29) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
13 |
7.4 |
d |
1.2 |
4.33 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68230 |
829 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
male |
65 days-112 days |
22 |
15.8 |
d |
1.9 |
8.9 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69489 |
837 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
13 |
10.1 |
d |
2.63 |
9.5 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69377 |
837 |
LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
|
2592000.0 |
|
0 |
|
|
|
110803 |
3186 |
LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
4 |
11.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
|
2592000.0 |
|
0 |
|
|
|
110801 |
3186 |
LOU/M |
experimental autoimmune encephalomyelitis duration |
rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
3 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
110789 |
3186 |
LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
3 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
|
2592000.0 |
|
0 |
|
|
|
110802 |
3186 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 28 |
10.7 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
37 |
days |
from 8 to 37 days |
days |
69381 |
892 |
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 19 |
11.8 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
31 |
days |
from 8 to 31days |
days |
69399 |
892 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
13.0 |
d |
1.8 |
5.09 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68197 |
829 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
16.4 |
d |
2.6 |
7.35 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68200 |
829 |
DA.ACI-(D10Rat15-D10Rat29) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
4 |
8.7 |
d |
2.8 |
5.6 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68212 |
829 |
LOU/M |
experimental autoimmune encephalomyelitis duration |
Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) |
Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20. |
central nervous system integrity trait |
not specified |
95 days-114 days |
5 |
8.0 |
d |
0.0 |
0.0 |
in vivo visual assessment |
|
2592000.0 |
|
0 |
|
|
|
110800 |
3186 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 21 |
11.5 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
28 |
days |
from 8 to 28 days |
|
69419 |
892 |
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 10 |
2.7 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
34 |
days |
from 8 to 34 days |
|
69428 |
892 |
DA/Ztm |
experimental autoimmune encephalomyelitis duration |
spinal cord homogenate (10 mg) |
Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 |
central nervous system integrity trait |
male |
56 days-103 days |
9 |
9.0 |
d |
2.67 |
8.0 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69953 |
1258 |
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 10 |
22.6 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
31 |
days |
from 8 to 31days |
days |
69396 |
892 |
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 21 |
13.3 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
28 |
days |
from 8 to 28 days |
|
69423 |
892 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
12 |
19.7 |
d |
2.48 |
8.6 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69376 |
837 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 18 |
20.9 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
38 |
days |
from 8 to 38 days |
days |
69393 |
892 |
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 11 |
17.6 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
38 |
days |
from 8 to 38days |
|
69408 |
892 |
DA.ACI-(D10Rat15-D10Rat29) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
12 |
3.5 |
d |
1.7 |
5.89 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68194 |
829 |
DA.ACI-(D10Rat2-D10Rat6) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
8 |
18.9 |
d |
2.2 |
6.22 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68206 |
829 |
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 16 |
4.9 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
40 |
days |
from 8 to 40 days |
days |
69389 |
892 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 18 |
14.3 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
31 |
days |
from 8 to 31 days |
days |
69392 |
892 |
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 18 |
6.0 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
34 |
days |
from 8 to 34 days |
|
69430 |
892 |
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) |
Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. |
central nervous system integrity trait |
female |
0 days
| 6 |
7.5 |
d |
|
|
in vivo visual assessment |
|
0.0 |
subcutaneous injection |
34 |
days |
from 8 to 34 days |
|
69437 |
892 |
DA.ACI-(D10Rat12-D10Rat144) |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
7 |
14.4 |
d |
2.8 |
7.41 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68221 |
829 |
DA/ZtmKini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (200 ul) |
Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. |
central nervous system integrity trait |
not specified |
63 days-105 days |
14 |
18.5 |
d |
1.6 |
5.99 |
in vivo visual assessment |
whole animal |
0.0 |
injection |
40 |
days |
range 31 to 40 days |
|
68224 |
829 |
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini |
experimental autoimmune encephalomyelitis duration |
myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) |
Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. |
central nervous system integrity trait |
female |
65 days-112 days |
0 |
10.1 |
d |
|
9.5 |
in vivo visual assessment |
|
0.0 |
|
0 |
|
|
|
69502 |
837 |